KIT and neoplasm: Among these patients, those who had CD117-expressing tumours had shorter survival than those with CD117-negative tumours (P < 0.001); the median survival time for the former was 50.0 months (95% CI 34.7–65.4), and for the latter was 111.4 months (95% CI 99.1–123.7).